Top

International Journal of Clinical Oncology

Published in:

01-02-2019 | Invited Review Article

Next-generation sequencing-based clinical sequencing: toward precision medicine in solid tumors

Authors: Toshifumi Wakai, Pankaj Prasoon, Yuki Hirose, Yoshifumi Shimada, Hiroshi Ichikawa, Masayuki Nagahashi

Published in: International Journal of Clinical Oncology | Issue 2/2019

Abstract

Numerous technical and functional advances in next-generation sequencing (NGS) have led to the adoption of this technique in conventional clinical practice. Recently, large-scale genomic research and NGS technological innovation have revealed many more details of somatic and germline mutations in solid tumors. This development is allowing for the classification of tumor type sub-categories based on genetic alterations in solid tumors, and based on this information, new drugs and targeted therapies are being administered to patients. This has largely been facilitated by gene panel testing, which allows for a better understanding of the genetic basis for an individual’s response to therapy. NGS-based comprehensive gene panel testing is a clinically useful approach to investigate genomic mechanisms, including therapy-related signaling pathways, microsatellite instability, hypermutated phenotypes, and tumor mutation burden. In this review, we describe the concept of precision medicine in solid tumors using NGS-based comprehensive gene panel testing, as well as the importance of quality control of tissue sample handling in routine NGS-based genomic testing, and we discuss issues for the future adoption of this technique in Japan.

Reuter JA, Spacek DV, Snyder MP (2015) High-throughput sequencing technologies. Mol Cell 58:586–597CrossRefPubMedPubMedCentral

Gerlinger M, Rowan AJ, Horswell S et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883–892CrossRefPubMedPubMedCentral

Shyr D, Liu Q (2013) Next generation sequencing in cancer research and clinical application. Biol Proced Online 15:4CrossRefPubMedPubMedCentral

Akbani R, Ng PK, Werner HM et al (2014) A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun 5:3887CrossRefPubMed

Robson ME, Bradbury AR, Arun B et al (2015) American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. J Clin Oncol 33:3660–3667CrossRefPubMed

Stanislaw C, Xue Y, Wilcox WR (2016) Genetic evaluation and testing for hereditary forms of cancer in the era of next-generation sequencing. Cancer Biol Med 13:55–67CrossRefPubMedPubMedCentral

Pleasance ED, Cheetham RK, Stephens PJ et al (2010) A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463:191–196CrossRefPubMed

Weinstein JN, Collisson EA, Mills GB et al (2013) The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 45:1113–1120CrossRefPubMedPubMedCentral

Futreal PA, Coin L, Marshall M et al (2004) A census of human cancer genes. Nat Rev Cancer 4:177–183CrossRefPubMedPubMedCentral

10.

Forbes SA, Beare D, Gunasekaran P et al (2015) COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res 43:D805–D811CrossRefPubMed

11.

Vogelstein B, Papadopoulos N, Velculescu VE et al (2013) Cancer genome landscapes. Science 339:1546–1558CrossRefPubMedPubMedCentral

12.

Stratton MR, Campbell PJ, Futreal PA (2009) The cancer genome. Nature 458:719–724CrossRefPubMedPubMedCentral

13.

Ellis MJ, Perou CM (2013) The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov 3:27–34CrossRefPubMedPubMedCentral

14.

Clinical Lung Cancer Genome Project (CLCGP); Network Genomic Medicine (NGM) (2013) A genomics-based classification of human lung tumors. Sci Transl Med 5:209ra153CrossRef

15.

Wu K, Huang RS, House L et al (2013) Next-generation sequencing for lung cancer. Future Oncol 9:1323–1336CrossRefPubMed

16.

Lianos GD, Mangano A, Cho WC et al (2015) From standard to new genome-based therapy of gastric cancer. Expert Rev Gastroenterol Hepatol 9:1023–1026CrossRefPubMed

17.

Nagahashi M, Shimada Y, Ichikawa H et al (2018) Next generation sequencing-based gene panel tests for the management of solid tumor. Cancer Sci. https://doi.org/10.1111/cas.13837 CrossRefPubMedPubMedCentral

18.

Varmus H (2003) Genomic empowerment: the importance of public databases. Nat Genet 35(Suppl 1):3CrossRefPubMed

19.

Varmus H, Stillman B (2005) Support for the Human Cancer Genome Project. Science 310:1615CrossRefPubMed

20.

Wheeler DA, Wang L (2013) From human genome to cancer genome: the first decade. Genome Res 23:1054–1062CrossRefPubMedPubMedCentral

21.

Endrullat C, Glokler J, Franke P et al (2016) Standardization and quality management in next-generation sequencing. Appl Transl Genom 10:2–9CrossRefPubMedPubMedCentral

22.

Nagahashi M, Shimada Y, Ichikawa H et al (2017) Formalin-fixed paraffin-embedded sample conditions for deep next generation sequencing. J Surg Res 220:125–132CrossRefPubMedPubMedCentral

23.

Arreaza G, Qiu P, Pang L et al (2016) Pre-analytical considerations for successful next-generation Sequencing (NGS): challenges and opportunities for formalin-fixed and paraffin-embedded tumor tissue (FFPE) samples. Int J Mol Sci 17(9):1579CrossRefPubMedCentral

24.

Stephens PJ, Greenman CD, Fu B et al (2011) Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144:27–40CrossRefPubMedPubMedCentral

25.

Baca SC, Prandi D, Lawrence MS et al (2013) Punctuated evolution of prostate cancer genomes. Cell 153:666–677CrossRefPubMedPubMedCentral

26.

Kandoth C, McLellan MD, Vandin F et al (2013) Mutational landscape and significance across 12 major cancer types. Nature 502:333–339CrossRefPubMedPubMedCentral

27.

Le Tourneau C, Delord JP, Goncalves A et al (2015) Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 16:1324–1334CrossRefPubMed

28.

Xue Y, Ankala A, Wilcox WR et al (2015) Solving the molecular diagnostic testing conundrum for Mendelian disorders in the era of next-generation sequencing: single-gene, gene panel, or exome/genome sequencing. Genet Med 17:444–451CrossRefPubMed

29.

Horak P, Fröhling S, Glimm H (2016) Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls. ESMO Open 1(5):e000094CrossRefPubMedPubMedCentral

30.

Garraway LA, Lander ES (2013) Lessons from the cancer genome. Cell 153:17–37CrossRefPubMed

31.

Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723CrossRefPubMedPubMedCentral

32.

Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135CrossRefPubMedPubMedCentral

33.

Yuza K, Nagahashi M, Watanabe S et al (2017) Hypermutation and microsatellite instability in gastrointestinal cancers. Oncotarget 8:112103–112115CrossRefPubMedPubMedCentral

34.

Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330–337CrossRef

35.

Nagahashi M, Wakai T, Shimada Y et al (2016) Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine. Genome Med 8:136CrossRefPubMedPubMedCentral

36.

Mensenkamp AR, Vogelaar IP, van Zelst-Stams WA et al (2014) Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. Gastroenterology 146:643–646.e648CrossRefPubMed

37.

Kautto EA, Bonneville R, Miya J et al (2017) Performance evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS. Oncotarget 8:7452–7463CrossRefPubMed

38.

Hause RJ, Pritchard CC, Shendure J et al (2016) Classification and characterization of microsatellite instability across 18 cancer types. Nat Med 22:1342–1350CrossRefPubMed

39.

Ichikawa H, Nagahashi M, Shimada Y et al (2017) Actionable gene-based classification toward precision medicine in gastric cancer. Genome Med 9:93CrossRefPubMedPubMedCentral

40.

Hoelder S, Clarke PA, Workman P (2012) Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol 6:155–176CrossRefPubMedPubMedCentral

41.

Ledford H (2010) Big science: the cancer genome challenge. Nature 464:972–974CrossRefPubMed

42.

Chang F, Li MM (2013) Clinical application of amplicon-based next-generation sequencing in cancer. Cancer Genet 206:413–419CrossRefPubMed

43.

Van Allen EM, Wagle N, Levy MA (2013) Clinical analysis and interpretation of cancer genome data. J Clin Oncol 31:1825–1833CrossRefPubMedPubMedCentral

44.

Hampel H, Bennett RL, Buchanan A, Pearlman R et al (2015) A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med 17:70–87CrossRefPubMed

45.

Desmedt C, Voet T, Sotiriou C et al (2012) Next-generation sequencing in breast cancer: first take home messages. Curr Opin Oncol 24:597–604CrossRefPubMedPubMedCentral

46.

LeBlanc VG, Marra MA (2015) Next-generation sequencing approaches in cancer: where have they brought us and where will they take us? Cancers (Basel) 7:1925–1958CrossRef

47.

Giuliano AE, Connolly JL, Edge SB et al (2017) Breast cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67:290–303CrossRefPubMed

48.

Buchtel KM, Vogel Postula KJ, Weiss S et al (2018) FDA approval of PARP inhibitors and the impact on genetic counseling and genetic testing practices. J Genet Couns 27:131–139CrossRefPubMed

49.

Imai S, Ichikawa T, Sugiyama C et al (2018) Contribution of Human Liver and Intestinal Carboxylesterases to the Hydrolysis of Selexipag In Vitro. J Pharm Sci. https://doi.org/10.1016/j.xphs.2018.09.022 CrossRefPubMed

50.

Moreira RB, Alessandretti MB, Abrahao CM et al (2015) Next-generation sequencing (NGS) in metastatic gastrointestinal cancer (mGIC) patients: translation from sequence data into clinical practice. J Clin Oncol 33:72–72CrossRef

51.

Lerner-Ellis J, Khalouei S, Sopik V (2015) Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer. Expert Rev Anticancer Ther 15:1315–1326CrossRefPubMed

52.

Hyman DM, Piha-Paul SA, Won H et al (2018) HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554:189–194CrossRefPubMedPubMedCentral

53.

Lowes LE, Bratman SV, Dittamore R et al (2016) Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA) Workshop 2016: Scientific Opportunities and Logistics for Cancer Clinical Trial Incorporation. Int J Mol Sci. https://doi.org/10.3390/ijms17091505 CrossRefPubMedPubMedCentral

54.

Shimomura A, Shiino S, Kawauchi J et al (2016) Novel combination of serum microRNA for detecting breast cancer in the early stage. Cancer Sci 107:326–334CrossRefPubMedPubMedCentral

Title: Next-generation sequencing-based clinical sequencing: toward precision medicine in solid tumors
Authors: Toshifumi Wakai
Pankaj Prasoon
Yuki Hirose
Yoshifumi Shimada
Hiroshi Ichikawa
Masayuki Nagahashi
Publication date: 01-02-2019
Publisher: Springer Singapore
Published in: International Journal of Clinical Oncology / Issue 2/2019
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-018-1375-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2019

Low-dose Gamma Knife radiosurgery plus whole-brain radiation therapy for patients with 5 or more brain metastases with or without meningeal dissemination

Burden of cardiovascular disease in Japanese cancer patients and survivors: a single cancer-center study in Niigata City

Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients

Gestational trophoblastic neoplasia with brain metastasis at initial presentation: a retrospective study

Correlations between CYP3A4 polymorphism and susceptibility to breast cancer in Chinese Han population

Clinical target sequencing for precision medicine of breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer